Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help prevent COVID-19. As with other drugs, Novavax can cause side effects, such as pain or swelling at the injection site ...

Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a ...

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year. The company now expects $650 million to $700 million in ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novavax, Inc. (Symbol: NVAX) entered into oversold territory, hitting an RSI reading of 28. ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...